ERIC Urges Senate Finance Committee to Reform the Entire Prescription Drug Supply Chain to Lower Costs for Patients

Washington –The ERISA Industry Committee (ERIC) submitted a letter to Senate Finance Committee Minority Staff responding to the Committee’s Request for Information (RFI) on Commonsense Policy Options to Lower Drug Prices for Patients. The letter lays out targeted reforms ERIC says would lower prescription drug costs for more than 160 million Americans who receive health coverage through their employers.

“Families and employers are being squeezed by a drug pricing system that is stacked against patients and the employers who offer them health benefits,” said James Gelfand, President and CEO of ERIC. “Congress has a real opportunity here, from fixing PBM and wholesaler practices that inflate costs, to closing patent loopholes that keep affordable generics and biosimilars off the market, and ending a crazy system that essentially pays providers commissions based on drugs’ list prices. We look forward to working with the Committee on solutions that actually lower costs for workers and their families.”

The letter urges support for the PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act (S. 3549), which would hold PBMs to fiduciary standards, and the PBM Kickback Prohibition Act (H.R. 7895), which would bar undisclosed payments to brokers who steer PBM business. It urges Congress to apply similar reforms to other parts of the supply chain – including wholesalers – that were recently applied to PBMs.

ERIC also asks Congress to direct the Congressional Budget Office (CBO) to study physician-administered drug costs under commercial plans, pursue site-neutral payment policies, and to end significant perverse incentives currently in place for hospitals.

On the patent system, ERIC’s letter backs a slate of bills to curb patent thickets and end market delay tactics, including the Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276), the Biosimilar Red Tape Elimination Act (S. 1954), and the Medication Affordability and Patent Integrity Act (S. 2658).

ERIC’s full letter to the Senate Finance Committee is available here.

###

All media inquiries to The ERISA Industry Committee should be directed to media@eric.org.

About The ERISA Industry Committee
ERIC is a national advocacy organization that exclusively represents large employers that provide health, retirement, paid leave, and other benefits to their nationwide workforces. With member companies that are leaders in every sector of the economy, ERIC advocates on the federal, state, and local levels for policies that promote flexibility and uniformity in the administration of their employee benefit plans.